DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

A Pilot Study Assessing EmSam in Bipolar Depression

Information source: New York State Psychiatric Institute
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Bipolar Depression

Intervention: EmSam (Drug)

Phase: Phase 4

Status: Terminated

Sponsored by: New York State Psychiatric Institute

Official(s) and/or principal investigator(s):
Deborah Deliyannides, M.D., Principal Investigator, Affiliation: New York State Psychiatric Institute


This pilot study will evaluate the efficacy of the monoamine oxidase inhibitor (MAOI)EmSam, a selegiline transdermal system (STS), in bipolar depression.

Clinical Details

Official title: A Pilot Study Assessing Efficacy, Safety, and Tolerability of EmSam in Bipolar Depression

Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Reduction of Depression CGI Score (<= 2)

Detailed description: Most current treatments for bipolar depression have been shown to be of modest effectiveness. There is some literature which suggests that Monoamine Oxidase Inhibitors (MAOIs) have greater efficacy than tricyclic antidepressants, and that they are effective for treatment-resistant depression of all types, both unipolar and bipolar. The MAOI selegiline has demonstrated antidepressant efficacy. EmSam, a selegiline transdermal system, provides central nervous system but not intestinal/liver MAO inhibition without clinically significant increases in sensitivity to dietary tyramine. This transdermal system appears to be associated with fewer side effects and increased safety relative to oral MAOI's. This pilot study will evaluate the efficacy of EmSam in bipolar depression.


Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.


Inclusion Criteria:

1. Ages 18 - 65

2. DSM-IV Bipolar Disorder (I, II, NOS), Depressed Phase 3. DSM-IV Bipolar Disorder (I,II, NOS), Mixed state with adequate mood stabilization (ie, resolution of manic or hypomanic symptoms for 8 weeks with a minimum of 4 weeks on a stable dose of mood-stabilizing medication that will be continued through all phases of the study). 4. Prior failure of or inability to tolerate at least one other antidepressant treatment 5. Physically healthy 6. Agrees to participate in the study 7. HAM-D 24 > 10 Exclusion Criteria: 1. Bipolar Disorder (I, II, NOS), Mixed State without adequate mood stabilization 2. Prior significant adverse reaction to EmSam 3. Unstable medical disorder 4. History of epilepsy (febrile seizure o. k.) 5. Current use of any medication that might interact with EnSam. 6. Use within 2 weeks of other antidepressant medication (6 weeks for fluoxetine) 7. Inability to adhere to a tyramine-free diet 8. Recent (past 6 months) suicide attempt 9. Serious suicidal ideation 10. Pregnant 11. Breast feeding 12. Fecund, sexually active females, without adequate contraception 13. Prior failure to respond to 2 or more adequate oral MAOI trials (2/3 PDR maximum dose, minimum 4 weeks) 14. Non-nicotine substance abuse/dependence within the past 6 months (1 year for amphetamines/cocaine)

Locations and Contacts

New York State Psychiatric Institute, New York, New York 10032, United States
Additional Information

DES official site

Columbia University clinical trials website

Starting date: March 2007
Last updated: October 24, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017